🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Cases of gonorrhoea are increasing around the world, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has classified it as a "critical concern". Recent surveillance found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Experts believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in concurrent days. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Data and Worldwide Availability

Based on findings published in a major medical journal, the new drug successfully treated the vast majority of uncomplicated infections. This places it at an equal footing with the typical regimen, which involves a dual-drug approach. The study enrolled nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in many developing nations.

Medical professionals directly involved have voiced positive views. Access to a single-dose, oral treatment such as this is hailed as a "game-changer" for public health efforts. This is viewed as vital to alleviate the strain of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.